Aurinia Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $83.22M | $0.28 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $77.70M | $0.25 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $77.10M | $1.53 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $73.47M | $0.23 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $70.00M | $0.16 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | $62.50M | $0.16 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $59.90M | $0.01 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $67.80M | $0.10 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 5, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net product sales | 2026 | $305.00M to $315.00M | Maintained |
| total revenue | 2026 | $315.00M to $325.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Aurinia Pharmaceuticals filed with the SEC
Aurinia Settles Patent Litigation with Teva
Other events · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
® Third Quarter 2025 Update November 4, 2025
Results of operations · EX-99.2 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Results of operations · Other events · EX-99.1 to Form 8-K
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Other events · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results,
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2023 NET REVENUE RESULTS
Results of operations · EX-99.1 to Form 8-K
AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Executive or director change · Other events · EX-99.1 to Form 8-K
AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
Renal Biopsy Sub-study April 2023
Regulation FD disclosure · EX-99.2 to Form 8-K
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES
Results of operations · EX-99.1 to Form 8-K
AURINIA PROVIDES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL-YEAR 2022 NET REVENUE RESULTS
Results of operations · EX-99.1 to Form 8-K
AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AURINIA REPORTS SECOND QUARTER AND SIX MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND COMPANY UPDATES
Results of operations · EX-99.1 to Form 8-K
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin Updated January 2022
Regulation FD disclosure · EX-99.1 to Form 8-K/A
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin December 9, 2021
Regulation FD disclosure · EX-99.1 to Form 8-K
AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES
Results of operations · EX-99.1 to Form 8-K